White House drops Trump’s FDA pick amid senators’ opposition and ‘icy’ relationship with RFK Jr.
By Adam Cancryn, Sarah Owermohle, CNN
(CNN) — The White House abruptly pulled its nominee to lead the Food and Drug Administration late Tuesday amid what Trump officials saw as skepticism from multiple Senate Republicans, a White House official and two other people familiar with the matter told CNN.
The decision to drop the nomination of Dr. Heidi Overton, a senior White House aide, came the night before a Senate committee was due to vote on whether to advance her nomination.
The committee’s chair, Sen. Bill Cassidy, maintained Tuesday night that she was on the verge of garnering enough support.
“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Cassidy wrote in a post on X shortly after her nomination was pulled. “This was odd as I was having productive conversations with members. I believe she would have had the votes to pass out of committee and pass the full Senate.”
The White House did not immediately comment on Cassidy’s contention. But officials’ decision to pull Overton’s nomination marked the culmination of weeks of intensifying scrutiny over her ability from both Republican senators and activists aligned with Health and Human Services Secretary Robert F. Kennedy Jr.
Trump officials had spent recent days working to fend off threats to sink Overton’s nomination by conservative Sen. Josh Hawley and the broader anti-abortion movement, which has been infuriated by the administration’s lack of urgency in restricting distribution of mifepristone, two people familiar with the matter said.
At the same time, Overton faced concerns from abortion rights proponents Sens. Susan Collins and Lisa Murkowski over her strident support for anti-abortion policies and role in the administration’s approval of flavored vapes.
Her nomination also exposed fault lines between the “Make America Healthy Again” movement, led by Kennedy, and more traditional conservative circles.
As a senior White House domestic policy aide, Overton spent the past year and a half as the main conduit between HHS leaders working to advance a handful of key MAHA policies and top Trump White House officials who have stalled them in recent months — sowing frustration and distrust within the broader MAHA movement.
Though Kennedy praised her nomination in August, those familiar with the dynamics between them have described the relationship as less than close.
Asked shortly after her selection for FDA commissioner about Overton’s relationship with Kennedy, one person familiar with the dynamic bluntly characterized it as “not good.”
Another called their interactions “icy.”
“She’s not MAHA,” said the second person familiar with the dynamic.
Nevertheless, Cassidy contended on Tuesday that Overton had a path to confirmation, writing that “pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues.”
“The Administration withdrew Dr. Overton rather than make such commitments,” he added.
Overton is just the latest health care nominee to be pulled amid crumbling GOP support; the White House has also yanked nominees to lead the Centers for Disease Control and Prevention and the surgeon general’s office as moderate Republicans voiced concerns.
The move is now likely to leave the FDA without a permanent leader well into next year. In his X post, Cassidy appeared to rule out considering another nominee before Republicans lose control of the Senate in January, writing: “Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”
A nomination in trouble
When Overton met privately with Cassidy, the outgoing Louisiana senator and physician, last week, the discussion had seemed to go well for the nominee.
She and her team emerged from the high-stakes sit-down confident in her candidacy for the top health job, two people briefed on the matter said, and Cassidy scheduled the committee vote for her shortly afterward, though he did not publicly endorse her.
But signs of fracturing support for her soon emerged. In the past week, posters have been popping up across Washington, DC, neighborhoods, urging senators to “say no to Heidi Vaperton for FDA commissioner,” claiming she is “pro-big tobacco” and “pro-abortion ban.”
The posters were organized by Health in Office, a nonpartisan group concerned about the administration’s health agenda, as The Washington Post first reported. The group’s spokesperson Jenny Kay declined to say who funded the project but said the activists behind the project have “a lot of concerns around who has already been put in charge of the health of people in this country.”
Despite their meeting last week, Cassidy signaled as recently as Sunday that a question mark hung over her nomination.
“I don’t know that” she has enough votes, he told CBS’ “Face the Nation.”
“I still have questions, and so I cannot tell you the outcome of that vote right now.”
Collins, another key Republican whose vote was needed, had also been publicly noncommittal about her vote. During Overton’s confirmation hearing, she questioned the nominee about her stance on flavored vapes, following reports that disagreements between the White House and former FDA Commissioner Dr. Marty Makary over greenlighting fruity e-cigarettes. The dispute ultimately led to the commissioner’s exit in May.
The disputes over vapes were recently resurfaced in a lengthy podcast interview with Calley Means, a MAHA advocate and White House senior adviser who left the administration in October.
Overton, a doctor by training who then worked in public policy, worked to “relax standards on fruit flavored vapes,” he told “The Joe Rogan Experience.”
He also accused Overton, who was closely aligned with former White House chief of staff Susie Wiles, of putting corporate interests ahead of the MAHA health agenda.
Wiles’ support was critical in Overton’s selection to lead the FDA earlier this year, people familiar with the matter said. But since Wiles’ departure and replacement with Stephen Miller, the new chief of staff has moved quickly to put his stamp on the administration, including signaling greater support for Kennedy and the MAHA coalition that has long been skeptical of Overton’s candidacy.
There had also been internal rifts between Kennedy and Overton over glyphosate and other stalled MAHA goals, according to two people familiar with policy discussions.
Overton has not publicly commented on Means’ allegations. HHS did not respond to a request for comment.
The need for a quick replacement
The White House did not immediately comment on its decision to pull Overton’s nomination, or give a timeline for picking a new nominee.
Outgoing Kansas Sen. Roger Marshall, who lost his reelection bid this month, has expressed interest to the administration in the being picked for the FDA role, according to one person familiar with private discussions on the matter.
But it’s unclear whether Trump would pick him — and if he could win over enough of his Senate colleagues to be confirmed.
Marshall is a member of the Senate’s health committee and benefits from close relationships on the panel. But he has been one of the most ardent supporters of the Trump administration’s divisive “Make America Healthy Again” policies, including questioning the safety of vaccines in hearings that have pitted him against the committee’s chair, Cassidy, and other moderate Republicans.
In the hours after the news of Overton’s withdrawal, some MAHA advocates celebrated.
Vani Hari, a healthy food advocate known by her “Food Babe” blog, wrote on X: “Another one bites the dust.”
This story has been updated with additional details.
The-CNN-Wire
™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
